Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination

Read Time:1 Minute, 1 Second

Christopher Martin AllenShelby RamsamyAlexander William TarrPatrick Jason TigheWilliam Lucien IrvingRadu TanasescuJonathan Rhys EvansFirst published: 10 June 2021 article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ana.26144.


Whilst SARS-CoV-2 vaccines are very safe, we report four cases of the bifacial weakness with paraesthesias variant of Guillain-Barré syndrome (GBS) occurring within three weeks of vaccination with the Oxford-AstraZeneca SARS-CoV-2 vaccine. This rare neurological syndrome has previously been reported in association with SARS-CoV-2 infection itself. Our cases were given either intravenous immunoglobulin, oral steroids, or no treatment. We suggest vigilance for cases of bifacial weakness with paraesthesias variant GBS following vaccination for SARS-CoV-2 and that post-vaccination surveillance programs ensure robust data capture of this outcome, to assess for causality.

This article is protected by copyright. All rights reserved.

Categories: All Posts

Average Rating

5 Star
4 Star
3 Star
2 Star
1 Star
%d bloggers like this: